Follicular lymphoma · 10 regimens
Cost vs Efficacy · 3 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Fludarabine and Rituximab (FR) Variant #06 | — | R 117 749 | 28d | — | — | — | — | — |
FCM Variant #01 | — | R 13 494 | 28d | — | — | — | — | — |
Fludarabine monotherapy Variant #01 | — | R 11 691 | 28d | ~16.5 mo | ~52.9 mo | ~18 | ~R 210 435 PFS proxy · indirect | 4 |
FMP Variant #01 | — | R 10 509 | 21d | — | — | — | — | — |
CHOP Variant #13 | — | R 859 | 21d | ~15.5 mo | — | ~23 | ~R 19 749 PFS proxy · indirect | 4 |
Ofatumumab monotherapy N/A - secondary systemic drug | — | R 2 | 56d | ~8.1 mo | — | ~5 | ~R 9 PFS proxy · indirect | 4 |
131Iodine-Tositumomab monotherapy N/A - secondary systemic drug | — | R 0 | — | — | — | — | — | — |
Umbralisib monotherapy Variant #01 Partial | — | — | 28d | — | — | — | — | — |
Idelalisib monotherapy Variant #01 Partial | — | — | 28d | — | — | — | — | — |
Interferon alfa monotherapy Variant #01 Partial | — | — | 7d | — | — | — | — | — |
10 of 10 regimens shown